Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab …
WEB6 days ago · NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15. Cachexia is a common, life-threatening wasting condition that can ...
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab …
WEB5 days ago · NEW YORK, September 14, 2024--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its ...
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab
WEB5 days ago · NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its...
Pfizer says its experimental drug for deadly condition that causes ...
WEB6 days ago · Pfizer ’s experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial, the drugmaker said ...
New therapy shows promise in improving appetite, quality of life …
WEB4 days ago · The Pfizer-sponsored study enrolled 187 participants across the world — including 10 from Oregon Health & Science University, the most of any clinical trial site in North America — in a study to better understand if the therapy ponsegromab could help participants increase body weight and appetite, and help with other cachexia symptoms.
Ponsegromab for the Treatment of Cancer Cachexia
WEB5 days ago · Among patients with cancer cachexia and elevated GDF-15 levels, the inhibition of GDF-15 with ponsegromab resulted in increased weight gain and overall activity level and reduced cachexia...
Pfizer Highlights Diverse Oncology Portfolio and Combination …
WEBSep 11, 2024 · Two late-breaking presentations include longer-term results from BRAFTOVI ® + MEKTOVI ® PHAROS study in BRAF V600E-mutant metastatic NSCLC and new Phase 2 ponsegromab data in cancer cachexia. Encouraging early results for PD-L1 vedotin ADC, disitamab vedotin and the novel combination of CDK4 + CDK2 inhibitors highlight rapidly advancing ...
ESMO 2024: Pfizer’s cachexia drug provides meaningful weight gain
WEB3 days ago · Pfizer previously published Phase Ib data that demonstrated ponsegromab’s proof-of-mechanism in cancer cachexia patients, with robust suppression of unbound circulating GDF-15 levels observed.
WEBPonsegromab is a potent and selective humanized monoclonal antibody that inhibits GDF-15-mediated signaling. The primary objective of this study (NCT05546476) is to assess the effect of ponsegromab on body weight in patients with cancer, cachexia, and elevated circulating GDF-15 concentrations.
Drug breakthrough provides new hope for cancer patients with …
WEB1 hour ago · Scientists discovered that a drug, ponsegromab, blocks a hormone known as GDF-15 that regulates appetite and body weight. ... Drugmaker Pfizer supported the study, and released this news. This is ...
- Some results have been removed
Skip to content